Hematologic Oncology

The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.

Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.

Duvelisib demonstrated deep, durable responses and promising efficacy data across peripheral T-cell lymphoma subgroups.

Orca-Q Receives FDA RMAT Designation for High-Risk Hematologic Malignancies.

A data monitoring committee recommended halting the phase 3 FLASH2 trial investigating HyBryte in CTCL due to futility.

The FDA has granted breakthrough therapy designation to TERN-701 for the treatment of Ph-positive chronic myeloid leukemia in chronic phase.

Data from a real-world analysis demonstrated the efficacy and safety of CAR T-cell therapy in primary mediastinal B-cell lymphoma.

Tafasitamab in combination with rituximab and lenalidomide has been approved for relapsed or refractory follicular lymphoma in Australia.

Roswell Park Comprehensive Cancer Center launched a trial of a new CAR T-cell therapy for AML that has relapsed or persisted despite earlier treatment.

Sharon Castellino, MD, MSc, discusses the significance of the FDA approval of nivolumab plus AVD for stage III/IV classical Hodgkin lymphoma.

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

The allogeneic CAR T-cell therapy cema-cel improved MRD negativity rates vs observation as first-line consolidation in LBCL.

Ibrutinib given prior to apheresis was associated with improved outcomes with tisagenlecleucel vs postapheresis administration in relapsed/refractory LBCL.

Tara Graff, DO, details the role of CAR T-cell therapy in the relapsed/refractory diffuse large B-cell lymphoma treatment paradigm.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

GATA2 variants retain enhancer activity, alter differentiation, and may link inflammation to hematologic malignancy risk.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has extended the PDUFA date for the Orca-T BLA to July 6, 2026.

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.